Patent Baristas

A month ago, Robert Ambrogi’s LawSites ran a LawSites Poll: Your Top Legal Blog. Deemed “an experiment”, Robert hopes to use the poll to deal with the flood of law blogs. Robert wanted to know: What is the one law-related blog you feel you must read as regularly as possible? No fair naming your own. […]

I don’t know what it is about the recent uptick in conflict issues but now the Washington Post has reported that federal prosecutors have charged a senior scientist at the National Institutes of Health with conflict of interest for taking fees from a drug company that was involved with his government research. Dr. P. Trey […]

I received the following note from a reader asking if anyone would have suggestions on the following fact pattern: I am preparing a petition to revive a US application that has gone abandoned, we think unintentionally. There are a number of case specific issues, which are not expressly provided for in MPEP 711.03. In particular, […]

The Court of Appeals for the Federal Circuit held that the effectiveness of the prior art is not relevant but rather whether it describes the claimed invention sufficiently to enable a person of ordinary skill in the art to carry out the invention. After Impax sued Aventis in District Court for a declaratory judgment that […]

The Supreme Court today heard oral arguments in the case of KSR International v. Teleflex. Already a group named the Coalition for Patent Fairness sent in a press release that it “welcomes” the Supreme Court review of the case of KSR International v. Teleflex. It states: “By choosing to hear this patent case, the highest […]

Earlier, the Court of Appeals for the Federal Circuit affirmed a District Court’s decision that Transkaryotic Therapies Inc. (TKT) and Aventis Pharmaceuticals Inc. infringe Amgen’s erythropoietin (EPO) patent estate. Amgen Inc., v. Hoechst Marion Roussel, Inc. (Now Aventis) and Transkaryotic Therapies, Inc., (05-1157). The court’s decision upheld the validity of two of Amgen’s EPO patents […]

Conducting a thorough IP due diligence review is a critical aspect of successful tech deals – especially in the bioscience industry. The intellectual property at issue can make or break a deal. It is imperative that you know what you have (or are getting) is the real deal. When undertaking a due diligence review during […]

The doctrine of equivalents was upheld for AstraZenaca’s patent on Propofol, used to induce and maintain general anaesthesia and sedation in patients. After the district court found Mayne had infringed AstraZeneca’s U.S. Pat. Nos. 5,714,520, 5,731,355 and 5,731,356, literally and under the doctrine of equivalents, the CAFC found that the district court erred in its […]